Tag: biosimilars

23 Jan

Future Biosimilars: Upcoming Patent Expirations and Market Entry

Biosimilars are set to transform healthcare as major biologics like Keytruda and Eylea lose patent protection between 2025 and 2030. Learn how these complex, lower-cost alternatives are entering the market, what’s holding them back, and what it means for patients and providers.

16 Jan

Planning for Patent Expiry: What Patients and Healthcare Systems Need to Do Now

Patent expiry means big savings on drugs-but only if patients and healthcare systems plan ahead. Learn what to do before generics hit the market, how to avoid pitfalls, and why some drugs stay expensive even after patents expire.